Selective serotonin reuptake inhibitors in pediatric depression

Is the balance between benefits and risks favorable?

Christopher J. Kratochvil*, Benedetto Vitiello, John Walkup, Graham Emslie, Bruce D. Waslick, Elizabeth B. Weller, William J. Burke, John S. March

*Corresponding author for this work

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

Recent controversies surrounding the use of selective serotonin reuptake inhibitors (SSRIs) have highlighted the need to reassess potential benefits, as well as potential risks of this class of medications in the treatment of pediatric depression. The recent availability of data from meta-analyses of published and unpublished antidepressant trials, epidemiological studies, and the Treatment for Adolescents with Depression Study (TADS) has facilitated a reanalysis of this risk/benefit relationship. Despite reviewing similar data, various regulatory agencies have arrived at rather disparate conclusions regarding the data, resulting in continued controversy. Although all groups appear to agree that careful assessment, education regarding risks, and closer monitoring are essential for SSRIs, only the U.S. Food and Drug Administration (FDA) and the U.K. Medicine and Health Care Products Regulatory Agency maintain that an acceptable risk/benefit relationship exists for fluoxetine. The European Medicines Agency concluded that the SSRIs should not be used in the treatment of depression in children and adolescents. The authors of this review have taken into consideration many of these same data and offer a critical discussion of the pros and cons of SSRIs in pediatric depression. The authors have concluded that SSRIs-in particular, fluoxetine-do have a role in the treatment of pediatric depression.

Original languageEnglish (US)
Pages (from-to)11-24
Number of pages14
JournalJournal of Child and Adolescent Psychopharmacology
Volume16
Issue number1-2
DOIs
StatePublished - Feb 1 2006

Fingerprint

Serotonin Uptake Inhibitors
Pediatrics
Fluoxetine
United States Food and Drug Administration
Therapeutics
Antidepressive Agents
Meta-Analysis
Epidemiologic Studies
Medicine
Delivery of Health Care
Education

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Kratochvil, Christopher J. ; Vitiello, Benedetto ; Walkup, John ; Emslie, Graham ; Waslick, Bruce D. ; Weller, Elizabeth B. ; Burke, William J. ; March, John S. / Selective serotonin reuptake inhibitors in pediatric depression : Is the balance between benefits and risks favorable?. In: Journal of Child and Adolescent Psychopharmacology. 2006 ; Vol. 16, No. 1-2. pp. 11-24.
@article{9fd484ed2d234bfe8262505e97b5a84c,
title = "Selective serotonin reuptake inhibitors in pediatric depression: Is the balance between benefits and risks favorable?",
abstract = "Recent controversies surrounding the use of selective serotonin reuptake inhibitors (SSRIs) have highlighted the need to reassess potential benefits, as well as potential risks of this class of medications in the treatment of pediatric depression. The recent availability of data from meta-analyses of published and unpublished antidepressant trials, epidemiological studies, and the Treatment for Adolescents with Depression Study (TADS) has facilitated a reanalysis of this risk/benefit relationship. Despite reviewing similar data, various regulatory agencies have arrived at rather disparate conclusions regarding the data, resulting in continued controversy. Although all groups appear to agree that careful assessment, education regarding risks, and closer monitoring are essential for SSRIs, only the U.S. Food and Drug Administration (FDA) and the U.K. Medicine and Health Care Products Regulatory Agency maintain that an acceptable risk/benefit relationship exists for fluoxetine. The European Medicines Agency concluded that the SSRIs should not be used in the treatment of depression in children and adolescents. The authors of this review have taken into consideration many of these same data and offer a critical discussion of the pros and cons of SSRIs in pediatric depression. The authors have concluded that SSRIs-in particular, fluoxetine-do have a role in the treatment of pediatric depression.",
author = "Kratochvil, {Christopher J.} and Benedetto Vitiello and John Walkup and Graham Emslie and Waslick, {Bruce D.} and Weller, {Elizabeth B.} and Burke, {William J.} and March, {John S.}",
year = "2006",
month = "2",
day = "1",
doi = "10.1089/cap.2006.16.11",
language = "English (US)",
volume = "16",
pages = "11--24",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "1-2",

}

Selective serotonin reuptake inhibitors in pediatric depression : Is the balance between benefits and risks favorable? / Kratochvil, Christopher J.; Vitiello, Benedetto; Walkup, John; Emslie, Graham; Waslick, Bruce D.; Weller, Elizabeth B.; Burke, William J.; March, John S.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 16, No. 1-2, 01.02.2006, p. 11-24.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Selective serotonin reuptake inhibitors in pediatric depression

T2 - Is the balance between benefits and risks favorable?

AU - Kratochvil, Christopher J.

AU - Vitiello, Benedetto

AU - Walkup, John

AU - Emslie, Graham

AU - Waslick, Bruce D.

AU - Weller, Elizabeth B.

AU - Burke, William J.

AU - March, John S.

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Recent controversies surrounding the use of selective serotonin reuptake inhibitors (SSRIs) have highlighted the need to reassess potential benefits, as well as potential risks of this class of medications in the treatment of pediatric depression. The recent availability of data from meta-analyses of published and unpublished antidepressant trials, epidemiological studies, and the Treatment for Adolescents with Depression Study (TADS) has facilitated a reanalysis of this risk/benefit relationship. Despite reviewing similar data, various regulatory agencies have arrived at rather disparate conclusions regarding the data, resulting in continued controversy. Although all groups appear to agree that careful assessment, education regarding risks, and closer monitoring are essential for SSRIs, only the U.S. Food and Drug Administration (FDA) and the U.K. Medicine and Health Care Products Regulatory Agency maintain that an acceptable risk/benefit relationship exists for fluoxetine. The European Medicines Agency concluded that the SSRIs should not be used in the treatment of depression in children and adolescents. The authors of this review have taken into consideration many of these same data and offer a critical discussion of the pros and cons of SSRIs in pediatric depression. The authors have concluded that SSRIs-in particular, fluoxetine-do have a role in the treatment of pediatric depression.

AB - Recent controversies surrounding the use of selective serotonin reuptake inhibitors (SSRIs) have highlighted the need to reassess potential benefits, as well as potential risks of this class of medications in the treatment of pediatric depression. The recent availability of data from meta-analyses of published and unpublished antidepressant trials, epidemiological studies, and the Treatment for Adolescents with Depression Study (TADS) has facilitated a reanalysis of this risk/benefit relationship. Despite reviewing similar data, various regulatory agencies have arrived at rather disparate conclusions regarding the data, resulting in continued controversy. Although all groups appear to agree that careful assessment, education regarding risks, and closer monitoring are essential for SSRIs, only the U.S. Food and Drug Administration (FDA) and the U.K. Medicine and Health Care Products Regulatory Agency maintain that an acceptable risk/benefit relationship exists for fluoxetine. The European Medicines Agency concluded that the SSRIs should not be used in the treatment of depression in children and adolescents. The authors of this review have taken into consideration many of these same data and offer a critical discussion of the pros and cons of SSRIs in pediatric depression. The authors have concluded that SSRIs-in particular, fluoxetine-do have a role in the treatment of pediatric depression.

UR - http://www.scopus.com/inward/record.url?scp=33645819592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645819592&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.16.11

DO - 10.1089/cap.2006.16.11

M3 - Review article

VL - 16

SP - 11

EP - 24

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 1-2

ER -